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Abstract
Background: There is emerging evidence that antidepressants may be effective in preventing patients with non-
specific and psychotic-like prodromal symptoms, defined as patients at ultra-high risk (UHR) of psychotic disorder,
from transitioning to psychosis. However, the mechanism of such an effect is still unknown.
Methods: We report the case of a 19-year-old Japanese man determined to be at UHR of psychotic disorder in
whom fluvoxamine (one of the antidepressants with sigma-1 receptor agonism) showed preventive effects on
psychotic-like prodromal symptoms.
Results: Our patient’s depressive symptoms were reduced and maintained below remission as a result of
treatment with 100 mg/day of fluvoxamine. In addition, it is likely that an additional dose of fluvoxamine (50 mg/
day) improved his psychotic-like prodromal symptoms directly, independent of its antidepressive effects.
Conclusion: Fluvoxamine, a sigma-1 receptor agonist, may be effective in preventing patients at UHR of psychotic
disorder from onset of psychosis via its neuroprotective/neurotropic actions, independent of its antidepressive
effects.
Background
In the past decade there has been increasing interest in
the potential benefit of early pharmacological interven-
tion in psychotic disorders. Patients with psychotic dis-
orders show non-specific and psychotic-like prodromal
symptoms preceding the onset of frank psychosis. Inter-
estingly, there is emerging evidence that antidepressants
may be effective in preventing patients who are at ultra-
high risk (UHR) of psychotic disorder from transitioning
to psychosis [1]. However, it is still unknown whether
such prevention of psychosis onset by antidepressants is
due to their antidepressive effects, such as mood
improvement, or other pharmacological effects, such as
neuroprotection. We present the case of a patient at
UHR of psychotic disorder in which fluvoxamine, a
selective serotonin reuptake inhibitor (SSRI) adminis-
tered alone, prevented the onset of psychosis, indepen-
dent of its antidepressive effects.
Case presentation
The patient was a 19-year-old Japanese unmarried office
worker with no personal or familial history of psychia-
tric problems. On presentation he complained of dete-
rioration of his work performance. He had suffered
from anhedonia, insomnia, loss of appetite, concentra-
tion deficit, and a sense of guilt for over 1 month, and
was diagnosed with major depressive disorder according
to Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition, Text Revision (DSM-IV-TR) criteria.
His baseline score on the 17-item Hamilton Depression
Rating Scale (HAM-D) was 23 points [2], and his Global
Assessment of Functioning (GAF) score was 55 points
[3]. Treatment with 50 mg/day of fluvoxamine was
started. Then, 3 weeks later, his depressive symptoms
improved and his fluvoxamine dose was increased to
100 mg/day. At 7 months after the start of treatment,
his depressive symptoms disappeared (HAM-D score: 6).
During the next 5 months, his quality of life (QoL)
remained stable with satisfactory performance in his
work (GAF score: 80).
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work performance deteriorated suddenly (GAF: 65)
despite continuous treatment with 100 mg/day of flu-
voxamine, without any concurrent symptoms of depres-
sion such as depressive mood or anhedonia. Then, 2
months later, he reported having a peculiar, highly con-
fusing sensation that two work colleagues who were liv-
ing in the same dormitory had spoken ill of him,
unfairly accusing him of wearing unwashed clothes,
among other things. In response, he had begun to delay
his meal and bath times in order to shun contact with
them, and to do his laundry several times a day. His
QoL was highly disturbed and his work performance
h a dw o r s e n e da c c o r d i n g l y( G A F :5 0 ) .H i sd i s o r d e r e d
thoughts of persecution persisted for several months,
and he was therefore diagnosed with UHR (attenuated
psychosis group) under the criteria of the Comprehen-
sive Assessment of At-Risk Mental States [4]. His flu-
voxamine dose was increased to 125 mg/day. Then, 1
month later, he began to relax his efforts to avoid his
colleagues and his QoL improved (GAF: 65). His fluvox-
amine dose was further increased to 150 mg/day. At 1
month after that, he said brightly ‘Id o n ’tc a r ea b o u t
them so much’, and his QoL improved still further
(GAF: 80). Treatment with 150 mg/day of fluvoxamine
was maintained, and his QoL remained stable with satis-
factory performance in his work, which lasted for more
than 2 years of follow-up.
Ethical approval
The treatment of the reported case was made according
to standard clinical practice, and ethical approval was
obtained from the Ethics Committee of Sodegaura Sat-
sukidai Hospital, Japan.
Discussion
To the best of our knowledge, this is the first report
showing that fluvoxamine alone prevented a UHR
patient from onset of psychosis. In this case, the
patient’s depressive symptoms were reduced and main-
tained below remission as a result of treatment with 100
mg/day of fluvoxamine. Therefore, it is estimated that
t h ea d d i t i o n a ld o s eo ff l u v o x a m i n e( 5 0m g / d a y )
improved his psychotic-like prodromal symptoms
directly, independent of its antidepressive effects.
Although the treatment with fluvoxamine modified
the natural course of the case, psychotic-like symptoms
never appeared during the major depressive episode.
Furthermore, the patient’s idea of persecution by his
colleagues was odd and incongruent with his mood.
Therefore, we estimated that both his psychotic-like
symptoms and depressive symptoms were the prodromal
symptoms of a UHR patient, rather than symptoms of
psychotic major depression. Previously, Häfner et al.
studied untreated psychotic and depressive symptoms
retrospectively from onset until first admission, and
demonstrated that delusional misinterpretations or delu-
sional references were highly specific to schizophrenia
(80.3% schizophrenia vs 6.2% unipolar depression),
although the frequency of depressive symptoms showed
surprising similarities between the two studied groups
[5].
Although most antidepressants share blockade of sero-
tonin transporters as a core mechanism, we reported
that some antidepressants possess high to moderate affi-
nity for the endoplasmic reticulum protein sigma-1
receptors [6], which are implicated in neuroprotection
and neuronal plasticity [7-10]. Among all antidepres-
sants, including SSRIs and typical tricyclic antidepres-
sants, fluvoxamine has shown the most potent action at
sigma-1 receptors, suggesting that sigma-1 receptors
might be involved in fluvoxamine’sm e c h a n i s m so f
action [6]. In cell culture systems, fluvoxamine, but not
sertraline or paroxetine, stimulated nerve growth factor-
induced neurite outgrowth in PC12 cells, and the effect
of fluvoxamine was antagonized by treatment with the
selective sigma-1 receptor antagonist NE-100 [11,12],
suggesting that the agonism of fluvoxamine plays a role
in neuronal plasticity.
We have previously hypothesized that the sigma-1
receptor agonist fluvoxamine might reduce the risk of
subsequent transition to psychosis via its neuroprotec-
tive/neurotrophic actions [13]. To the best of our
knowledge, this is the first case report supporting our
hypothesis.
Conclusions
This case suggests that fluvoxamine, a sigma-1 receptor
agonist, may be effective in preventing patients at UHR
of psychotic disorder from onset of psychosis. More
detailed randomized, double-blind placebo-controlled
s t u d i e su s i n gal a r g es a m p l es i z ew i l lb en e e d e dt oc o n -
firm this.
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